Publication:
SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.

dc.contributor.authorNguyen, Dung
dc.contributor.authorSimmonds, Peter
dc.contributor.authorSteenhuis, Maurice
dc.contributor.authorWouters, Elise
dc.contributor.authorDesmecht, Daniel
dc.contributor.authorGarigliany, Mutien
dc.contributor.authorRomano, Marta
dc.contributor.authorBarbezange, Cyril
dc.contributor.authorMaes, Piet
dc.contributor.authorVan Holm, Bram
dc.contributor.authorMendoza, Joaquín
dc.contributor.authorOyonarte, Salvador
dc.contributor.authorFomsgaard, Anders
dc.contributor.authorLassaunière, Ria
dc.contributor.authorZusinaite, Eva
dc.contributor.authorResman Rus, Katarina
dc.contributor.authorAvšič-Županc, Tatjana
dc.contributor.authorReimerink, Johan Hj
dc.contributor.authorBrouwer, Fiona
dc.contributor.authorHoogerwerf, Marieke
dc.contributor.authorReusken, Chantal Bem
dc.contributor.authorGrodeland, Gunnveig
dc.contributor.authorLe Cam, Sophie
dc.contributor.authorGallian, Pierre
dc.contributor.authorAmroun, Abdennour
dc.contributor.authorBrisbarre, Nadège
dc.contributor.authorMartinaud, Christophe
dc.contributor.authorLeparc Goffart, Isabelle
dc.contributor.authorSchrezenmeier, Hubert
dc.contributor.authorFeys, Hendrik B
dc.contributor.authorvan der Schoot, C Ellen
dc.contributor.authorHarvala, Heli
dc.date.accessioned2023-02-09T11:43:00Z
dc.date.available2023-02-09T11:43:00Z
dc.date.issued2021
dc.description.abstractWe compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.
dc.identifier.doi10.2807/1560-7917.ES.2021.26.27.2100568
dc.identifier.essn1560-7917
dc.identifier.pmcPMC8268650
dc.identifier.pmid34240697
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268650/pdf
dc.identifier.unpaywallURLhttps://www.eurosurveillance.org/deliver/fulltext/eurosurveillance/26/27/eurosurv-26-27-2.pdf?itemId=%2Fcontent%2F10.2807%2F1560-7917.ES.2021.26.27.2100568&mimeType=pdf&containerItemId=content/eurosurveillance
dc.identifier.urihttp://hdl.handle.net/10668/18180
dc.issue.number27
dc.journal.titleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
dc.journal.titleabbreviationEuro Surveill
dc.language.isoen
dc.organizationC.T.S. Sevilla
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectEurope
dc.subjectSARS-CoV-2
dc.subjectconvalescent plasma
dc.subjectneutralising antibodies
dc.subjectstandardisation, COVID-19
dc.subject.meshAntibodies, Neutralizing
dc.subject.meshAntibodies, Viral
dc.subject.meshCOVID-19
dc.subject.meshEurope
dc.subject.meshHumans
dc.subject.meshImmunization, Passive
dc.subject.meshSARS-CoV-2
dc.subject.meshCOVID-19 Serotherapy
dc.titleSARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number26
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8268650.pdf
Size:
226.47 KB
Format:
Adobe Portable Document Format